Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial

Journal: Nature Medicine

Published: 2021-01-18

DOI: 10.1038/s41591-020-01189-2

Affiliations: 35

Authors: 32

Go to article
Institutions Share
Institute Gustave-Roussy (IGR), France 0.09
Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-Oncopole), France 0.08
Curie Institute, France 0.08
University of Paris-Saclay, France 0.08
UNICANCER Group, France 0.06
Molecular Predictors and New Targets in Oncology, France 0.04
Hôpitaux du Léman, France 0.03
Institut Sainte Catherine, France 0.03
University of Côte d'Azur (UCA), France 0.03
Centre Hospitalier Départemental de la Roche-sur-Yon, France 0.03
Centre François Baclesse, France 0.03
Centre Hospitalier Intercommunal de Toulon, France 0.03
Centre Georges-François Leclerc (CGFL), France 0.03
Centre Léon Bérard (CLB), France 0.03
Institut de Recherche en Cancérologie de Montpellier (IRCM), France 0.03
Centre Jean Perrin (CJP), France 0.03
Institut Paoli-Calmettes (IPC), France 0.03
Centre Eugène Marquis (CEM), France 0.03
Bergonié Cancer Institute, France 0.03
Institute of Cancer Research (ICO), France 0.03
Institut de Cancérologie Strasbourg Europe (ICANS), France 0.02
University Hospitals of Strasbourg (HUS), France 0.02
University of Rouen, France 0.02
Centre Henri Becquerel, France 0.02
University of Toulouse, France 0.02
University of Paris, France 0.02
Integrative Tumor Immunology and Genetic Oncology, France 0.02
University of Lyon, France 0.01
Lyon University Hospital (HCL), France 0.01
Centre Hospitalier Lyon-Sud, HCL, France 0.01

Return